ReviewTherapeutics and clinical risk management2019
Autosomal dominant polycystic kidney disease: updated perspectives.
Review in Therapeutics and clinical risk management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Autosomal Dominant Polycystic Kidney Disease Presenting as a Painless Epigastric Mass: A Case Report.The American journal of case reports · 2026Article
- Autosomal dominant polycystic kidney disease in children and adolescents.Childhood kidney diseases · 2026Review
- Kidney stones and autosomal dominant polycystic kidney disease: a state-of-the-art review.Renal failure · 2025Review
- Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.Renal failure · 2025Review
- Minimally Invasive Nephrectomy for the Management of Polycystic Kidney Disease: The Hilum-First Technique.Journal of clinical medicine · 2025Article
- Comparative validation of the Mayo Clinic imaging classification and PROPKD score for predicting ADPKD progression across diverse ethnic cohorts.Journal of nephrology · 2025Article
- The prospect of novel orphan therapeutic protocol for TSC2/PKD1 contiguous gene syndrome: a case report.BMC nephrology · 2025Article
- Prospects for gene therapy in polycystic kidney disease.Current opinion in nephrology and hypertension · 2025Review
- RETRACTED: Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease.Journal of personalized medicine · 2024Article
- Ocular manifestations of renal ciliopathies.Pediatric nephrology (Berlin, Germany) · 2024Review
- Autosomal dominant polycystic kidney disease (ADPKD) with multiple complications: Management challenges.Narra J · 2024Article
- Case Report: Autosomal dominant polycystic kidney disease and Wilms' tumor in infancy and childhood.Frontiers in pediatrics · 2024Article
- Severity of polycystic kidney disease revealed by multiparametric MRI.Magnetic resonance in medicine · 2023Article
- Metabolomic profiling to identify early urinary biomarkers and metabolic pathway alterations in autosomal dominant polycystic kidney disease.American journal of physiology. Renal physiology · 2023Article
- Gallbladder cancer concomitant with autosomal dominant polycystic kidney disease: A case report.Clinical case reports · 2022Article
- Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progression.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options.Kidney research and clinical practice · 2022Article
- Deep Learning-Enabled Technologies for Bioimage Analysis.Micromachines · 2022Review
- Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease.Therapeutics and clinical risk management · 2021Review
- Analysis of mutations in six Chinese families with autosomal dominant polycystic kidney disease.American journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited multisystem disorder, characterized by renal and extra-renal fluid-filled cyst formation and increased kidney volume that eventually leads to end-stage renal disease. ADPKD is considered the fourth leading cause of end-stage renal disease in the United States and globally. Care of patients with ADPKD was, for a long time, limited to supportive lifestyle measures, due to the lack of therapeutic strategies targeting the main pathways involved in the pathophysiology of ADPKD. As the first FDA approved treatment of ADPKD, Vasopressin (V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.